Saturday, 1 April 2017

In-Depth Research on Global Picture Archiving and Communication System Market 2017-2021

Report : Global Picture Archiving and Communication System Market 2017-2021 is a new market research publication announced by Reportstack. 
Report Outline: The global PACS market is witnessing continuous technological developments and innovations. The Americas was the major revenue contributor to the market in 2016, with the US dominating the market in the region. It was followed by EMEA There is, however, a huge opportunity for the market in APAC to grow at a faster rate and increase its revenue contribution during the forecast period.
For detailed report with TOC, please click here ​Global Picture Archiving and Communication System Market 2017-2021
Market Growth: The global PACS market to grow at a CAGR of 5.64% during the period 2017-2021.
Key vendors • GE Healthcare
• Philips
• Agfa-Gevaert
• McKesson
• Fujifilm
Other prominent vendors • AltaPACS
• Apollo Enterprise Imaging
• Ashva Digital Healthcare
• Carestream Health
• CERNER
• Dell
• Esaote SpA
• INFINITT Healthcare
• Insignia Medical Systems
• Intelerad Medical Systems
• Laitek
• Lexmark Healthcare
• Mach7 Technologies
• Meddiff Technologies
• Merge Healthcare (part of IBM company)
• Novarad
• Nuvodia
• Paxeramed
• ScImage
• Sectra
• Siemens Healthineers
• Velox RIS Solutions
• VEPRO
• Voyager Imaging
Regions Covered: 
• Americas
• APAC
• EMEA
Companies Mentioned
GE Healthcare, Philips, Agfa-Gevaert, McKesson, Fujifilm, AltaPACS, Apollo Enterprise Imaging, Ashva Digital Healthcare, Carestream Health, CERNER, Dell, Esaote SpA, INFINITT Healthcare, Insignia Medical Systems, Intelerad Medical Systems, Laitek, Lexmark Healthcare, Mach7 Technologies, Meddiff Technologies, Merge Healthcare, Novarad, Nuvodia, Paxeramed, ScImage, Sectra, Siemens Healthineers, Velox RIS Solutions, VEPRO, Voyager Imaging.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
Posted by at No comments:

Detailed Report on Natural Killer Cells Therapies, 2017

Natural Killer Cells Therapies- Competitive Landscape,Technology and Pipeline Analysis, 2017 is a new market research publication announced by Reportstack. This report emphasizes on the currently active NK cell therapy products and NK cell augmenters in research and development. 
The report covers 20+ companies, which are active in this field with 40+ products and many different technologies. This report covers NK cell based therapies and drugs that augment (enhance or activate) the NK cells. The report provides in-depth analysis on the Natural Killer Cell based therapies profiles along with the augmenting therapies covering their pre-clinical and clinical studies, collaborations details and deal values, technologies and targeted antigens. The report provides the NK Cell based therapies licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis. 
Reports Highlights:NK cell Therapy Pipeline scenario which includes NK cell therapies and NK cell augmenting therapies.
Collaborations & partnering deals
Current Prominent Research Areas and Key Players
Pipeline product profiles NK Cell therapy Technologies and NK cell Augmenting Therapies
Licensing opportunities 
Market Drivers and Barriers
Scope Overview of the global NK cell therapy and NK cell augmenting therapies pipeline scenario, products and associated companies information
Coverage of global NK cell therapies and drugs that enhance the activity of NK under development 
Competitive landscape of products for key players and related indications
Coverage of licensors, collaborators and development partners, deal terms and deal values estimation
Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
Highlights of licensing & collaboration opportunities and funding details
Highlights of latest NK cell therapy technologies and NK cell augmenting therapies and innovative companies
Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

New Report Explores on Microbiome, 2017

Microbiome- Competitive Landscape, Technology andPipeline Analysis, 2017 is a new market research publication announced by Reportstack. This report provides comprehensive insights about pipeline drugs across this class. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Microbiome. This report provides information on the therapeutic development based on the Microbiome dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. 
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by the team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Reports Highlights:Microbiome Pipeline scenario 
Collaborations & partnering deals
Current Prominent Research Areas and Key Players
Pipeline product profiles Microbiome Technologies
Licensing opportunities 
Market Drivers and Barriers
ScopeOverview of the global Microbiome pipeline scenario, products and associated companies information
Coverage of global Microbiome therapies under development 
Competitive landscape of products for key players and related indications
Coverage of licensors, collaborators and development partners, deal terms and deal values estimation
Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
Highlights of licensing & collaboration opportunities and funding details
Highlights of latest Microbiome technologies 
Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis
Reasons to BuyIdentify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
Complete MOA intelligence and complete understanding over therapeutics development for Microbiome therapies
Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
Devise corrective measures for pipeline projects by understanding Microbiome pipeline depth and focus of Indication therapeutics
Developing strategic initiatives to support your drug development activities.
Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

New Report Covers Chemotherapy Induced Nausea and Vomiting (CINV) 2023

Chemotherapy Induced Nausea and Vomiting (CINV) - Market Insights, Epidemiology and Market Forecast- 2023 is a new market research publication announced by Reportstack. This report provides an overview of the disease and global market size of the Chemotherapy Induced Nausea and Vomiting (CINV) for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the Incident cases of Chemotherapy Induced Nausea and Vomiting (CINV) from 2013-2023. 
Chemotherapy-induced nausea and vomiting (CINV) are both severe side effects of cancer treatment. CINV is a condition which makes a patient uncomfortable and has to be dealt properly as many patients delay their chemotherapy cycles or even refuse further treatment due to fear from future nausea and vomiting. Also, due to nausea and vomiting induced by chemotherapy, patients can’t get nutrition properly and lose their energy and may become weak which may hinder the further chemotherapy cycles as patient wouldn’t be physically string to bear the chemotherapy side-effects.
According to this report, the global market for Chemotherapy Induced Nausea and Vomiting (CINV) is estimated to be USD XX Million by 2023 at a CAGR of 8.32 % for the forecast period i.e., 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
The report will help in developing business strategies by understanding the trends shaping and driving the Chemotherapy Induced Nausea and Vomiting (CINV) market.
Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy Induced Nausea and Vomiting (CINV) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan. 
To understand the future market competition in the 7MM market of Chemotherapy Induced Nausea and Vomiting (CINV) and Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.
The Report also covers the detailed historical and forecasted Chemotherapy Induced Nausea and Vomiting (CINV)market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

Definition and Specifications of Interstitial Cystitis 2023

Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2023 is a new market research publication announced by Reportstack. This report provides an overview of the disease and global market trends of the Interstitial Cystitis for the seven major markets i.e. United States, Europe (France, Germany, Italy, Spain, UK) and Japan. 
The Report covers the therapeutics market revenue, treatment practice and Interstitial Cystitis forecasted market share from 2017 to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Interstitial Cystitis till 2023. Interstitial cystitis (IC) also known as painful bladder syndrome is a chronic disease that results in recurring discomfort or pain in the bladder and the surrounding pelvic region. This is considered as multiple bladder condition as it can lead to many other problems. 
Current studies estimate that 2.7% to 6.5% of women in the United States have symptoms consistent with a diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS). PBS/IC is more common in women, with a female/male ratio that ranges from 5:1 to 10:1 and the Median age at diagnosis is 42 to 46 yr old whereas men are diagnosed at a younger age. 
According to this report, the Interstitial Cystitis market for 7MM is estimated to be USD 427.2 Million by 2023 at a CAGR of (XX%). The number of Incident Probable IC cases is expected to reach 197,086 cases in 2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope The report will help in developing business strategies by understanding the trends shaping and driving the global Interstitial Cystitis market. 
Organize sales and marketing efforts by identifying the best opportunities for Interstitial Cystitis in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan. 
To understand the future market competition in the global Interstitial Cystitis market and Insightful review of the key market drivers and barriers. 
To understand the regulatory scenario in major markets. 
The Report also covers the detailed global historical and forecasted Interstitial Cystitis market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

In-Depth Research Analysis On Urinary Incontinence 2023-7MM

Urinary Incontinence - Market Insights, Epidemiology and Market Forecast -2023-7MM is a new market research publication announced by Reportstack. This report provides an overview of the disease and global market size of the Urinary Incontinence for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Urinary Incontinence from 2013-2023. 
Urinary Incontinence is a multifactorial syndrome which occurs due to the failure of the storage function of the lower urinary tract and loss of bladder control resulting in leakage of urine. Embarrassment, isolation, and depression are observed among patients with Urinary Incontinence. Millions of individuals worldwide are suffering from Urinary Incontinence. It is most common among the old people. It increases the chances of developing several medical conditions such as local skin irritation, rashes, and urinary infections.
According to this report, the market size for Urinary Incontinence of 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 9.5% for the forecast period i.e., 2013-2023. 
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
The report will help in developing business strategies by understanding the trends shaping and driving the Urinary Incontinence market.
Organize sales and marketing efforts by identifying the best opportunities for Urinary Incontinence in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan. 
To understand the future market competition in the 7MM market of Urinary Incontinence and Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.
The Report also covers the detailed historical and forecasted Urinary Incontinence market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

New Research Explores on Sarcopenia 2023-7 MM

Sarcopenia - Market Insights, Epidemiology and Market Forecast -2023-7 MM is a new market research publication announced by Reportstack. This report provides an overview of the disease and global market size of the Sarcopenia for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023. 
Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after age 30, but the resulting loss of strength increases exponentially with age. Of the contributory factors relating to the development of sarcopenia inadequate protein intake, increased splanchnic extraction of amino acids, decreased muscular response to postprandial anabolic stimuli and vitamin D deficiency are directly related to nutrition. 
According to this report, the market size of Sarcopenia in 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 2.36% for the forecast period i.e., 2013-2023. Also the prevalence cases in 7 MM are expected to increase and reach up to 42,969,489 cases by year 2023. 
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
The report will help in developing business strategies by understanding the trends shaping and driving the Sarcopenia market.
Organize sales and marketing efforts by identifying the best opportunities for Sarcopenia in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan. 
To understand the future market competition in the 7MM market of Sarcopenia and Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.
The Report also covers the detailed historical and forecasted Sarcopenia market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:
Subscribe to: Posts (Atom)